FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078996712> ?p ?o ?g. }

• W2078996712 endingPage "1364" @default.
• W2078996712 startingPage "1359" @default.
• W2078996712 abstract "The success of tamoxifen in reducing the occurrence of contralateral breast cancer among breast cancer patients in clinical trials has prompted the study of its use in the primary prevention of breast cancer. Long-term risks associated with tamoxifen therapy, however, are still being evaluated, particularly with respect to subsequent cancer occurrence at sites other than the breast.This population-based, nested case-control study investigated the risks of second primary cancers of the ovary, endometrium, and contralateral breast among women receiving tamoxifen for breast cancer in conventional medical practice.A cohort of women diagnosed with breast cancer during 1978 through 1990 was identified from a population-based cancer registry. Case subjects included all women in the cohort who subsequently developed second primary ovarian (n = 39), endometrial (n = 42), or contralateral breast (n = 234) cancer prior to 1992. Control subjects were a random sample of the cohort who did not develop a second primary malignancy; they were matched to the case subjects on age, disease stage, and year of initial breast cancer diagnosis (approximately two control subjects per case subject). Information on tamoxifen use as well as on potential risk factors for the second primary cancers was obtained through medical record abstractions and physician questionnaires.The percentage of women who had received tamoxifen was 18% and 20%, respectively, among ovarian cancer case subjects and control subjects; 26% and 31%, respectively, among endometrial cancer case subjects and control subjects; and 10% and 18%, respectively, among contralateral breast cancer case subjects and control subjects. The mean duration of tamoxifen use was less than 2 years for all groups. The relative risks for ovarian and endometrial cancers in women who took tamoxifen were relatively low but were consistent with no association (for ovarian cancer, matched odds ratio [mOR] = 0.6 and 95% confidence interval [CI] = 0.2-1.8; for endometrial cancer, mOR = 0.6 and 95% CI = 0.2-1.9). Tamoxifen therapy was associated with a decreased risk of contralateral breast cancer (mOR = 0.5; 95% CI = 0.3-0.9), especially if the drug had been taken for more than 1 year (mOR = 0.4; 95% CI = 0.2-0.9) or if the women were postmenopausal at initial breast cancer diagnosis (mOR = 0.4; 95% CI = 0.2-0.8).These data suggest that short durations of tamoxifen therapy are not associated with an increased risk of endometrial or ovarian cancer but are associated with a reduction in contralateral breast cancer risk. It would not be appropriate, however, to generalize these results to women who receive tamoxifen for longer periods." @default.
• W2078996712 created "2016-06-24" @default.
• W2078996712 creator A5005605475 @default.
• W2078996712 creator A5011298754 @default.
• W2078996712 creator A5016769319 @default.
• W2078996712 creator A5016958524 @default.
• W2078996712 creator A5053089585 @default.
• W2078996712 creator A5074466135 @default.
• W2078996712 creator A5075165389 @default.
• W2078996712 date "1995-09-20" @default.
• W2078996712 modified "2023-10-16" @default.
• W2078996712 title "Population-Based Study of Tamoxifen Therapy and Subsequent Ovarian, Endometrial, and Breast Cancers" @default.
• W2078996712 doi "https://doi.org/10.1093/jnci/87.18.1359" @default.
• W2078996712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7658496" @default.
• W2078996712 hasPublicationYear "1995" @default.
• W2078996712 type Work @default.
• W2078996712 sameAs 2078996712 @default.
• W2078996712 citedByCount "138" @default.
• W2078996712 countsByYear W20789967122012 @default.
• W2078996712 countsByYear W20789967122013 @default.
• W2078996712 countsByYear W20789967122014 @default.
• W2078996712 countsByYear W20789967122016 @default.
• W2078996712 countsByYear W20789967122017 @default.
• W2078996712 countsByYear W20789967122018 @default.
• W2078996712 countsByYear W20789967122019 @default.
• W2078996712 countsByYear W20789967122021 @default.
• W2078996712 countsByYear W20789967122022 @default.
• W2078996712 countsByYear W20789967122023 @default.
• W2078996712 crossrefType "journal-article" @default.
• W2078996712 hasAuthorship W2078996712A5005605475 @default.
• W2078996712 hasAuthorship W2078996712A5011298754 @default.
• W2078996712 hasAuthorship W2078996712A5016769319 @default.
• W2078996712 hasAuthorship W2078996712A5016958524 @default.
• W2078996712 hasAuthorship W2078996712A5053089585 @default.
• W2078996712 hasAuthorship W2078996712A5074466135 @default.
• W2078996712 hasAuthorship W2078996712A5075165389 @default.
• W2078996712 hasConcept C121608353 @default.
• W2078996712 hasConcept C126322002 @default.
• W2078996712 hasConcept C131872663 @default.
• W2078996712 hasConcept C143998085 @default.
• W2078996712 hasConcept C201903717 @default.
• W2078996712 hasConcept C2777088508 @default.
• W2078996712 hasConcept C2777176818 @default.
• W2078996712 hasConcept C2779880527 @default.
• W2078996712 hasConcept C2780427987 @default.
• W2078996712 hasConcept C2908647359 @default.
• W2078996712 hasConcept C29456083 @default.
• W2078996712 hasConcept C530470458 @default.
• W2078996712 hasConcept C71924100 @default.
• W2078996712 hasConcept C72563966 @default.
• W2078996712 hasConcept C99454951 @default.
• W2078996712 hasConceptScore W2078996712C121608353 @default.
• W2078996712 hasConceptScore W2078996712C126322002 @default.
• W2078996712 hasConceptScore W2078996712C131872663 @default.
• W2078996712 hasConceptScore W2078996712C143998085 @default.
• W2078996712 hasConceptScore W2078996712C201903717 @default.
• W2078996712 hasConceptScore W2078996712C2777088508 @default.
• W2078996712 hasConceptScore W2078996712C2777176818 @default.
• W2078996712 hasConceptScore W2078996712C2779880527 @default.
• W2078996712 hasConceptScore W2078996712C2780427987 @default.
• W2078996712 hasConceptScore W2078996712C2908647359 @default.
• W2078996712 hasConceptScore W2078996712C29456083 @default.
• W2078996712 hasConceptScore W2078996712C530470458 @default.
• W2078996712 hasConceptScore W2078996712C71924100 @default.
• W2078996712 hasConceptScore W2078996712C72563966 @default.
• W2078996712 hasConceptScore W2078996712C99454951 @default.
• W2078996712 hasIssue "18" @default.
• W2078996712 hasLocation W20789967121 @default.
• W2078996712 hasLocation W20789967122 @default.
• W2078996712 hasOpenAccess W2078996712 @default.
• W2078996712 hasPrimaryLocation W20789967121 @default.
• W2078996712 hasRelatedWork W174813307 @default.
• W2078996712 hasRelatedWork W1771722205 @default.
• W2078996712 hasRelatedWork W2015092588 @default.
• W2078996712 hasRelatedWork W2017804827 @default.
• W2078996712 hasRelatedWork W2027175481 @default.
• W2078996712 hasRelatedWork W2103643613 @default.
• W2078996712 hasRelatedWork W2172254302 @default.
• W2078996712 hasRelatedWork W2464051959 @default.
• W2078996712 hasRelatedWork W2998725311 @default.
• W2078996712 hasRelatedWork W57637140 @default.
• W2078996712 hasVolume "87" @default.
• W2078996712 isParatext "false" @default.
• W2078996712 isRetracted "false" @default.
• W2078996712 magId "2078996712" @default.
• W2078996712 workType "article" @default.